Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
NCT06311929

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Led by Chen Xiaoping · Updated on 2024-05-07

300

Participants Needed

1

Research Sites

247 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.

CONDITIONS

Official Title

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years
  • No previous local or systemic treatment for hepatocellular carcinoma
  • Child-Pugh liver function score of 7 or less
  • ECOG performance status of 0 or 1
  • No serious organic diseases of the heart, lungs, brain, kidneys, or other major organs
  • Pathologic diagnosis of hepatocellular carcinoma
  • Confirmed presence of VETC vascular pattern by CD34 immunohistochemical staining
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Conditions affecting absorption, distribution, metabolism, or clearance of study drugs (such as severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption)
  • History of gastrointestinal bleeding within 4 weeks or known risk factors for gastrointestinal bleeding not treated
  • Active infection
  • Significant clinical or laboratory abnormalities affecting safety evaluation
  • Inability to follow study protocol for treatment or scheduled follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Wuhan, Hubei, China, 430000

Actively Recruiting

Loading map...

Research Team

W

WanGuang Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma | DecenTrialz